SEC Comment Letter for Opus Genetics, Inc. (IRD) (CIK 0001228627) (IRD) — Nov 15, 2016
Opus Genetics, Inc. (IRD) (CIK 0001228627)
Date: Nov. 15, 2016 · CIK: 0001228627 · Accession: 0000000000-16-101002
AI Filing Summary & Sentiment
Reasoning
Letter
Mail Stop 4 546 November 15, 2016 Via E -mail Tae Heum Jeong Chief Financial Officer Rexahn Pharmaceuticals, Inc. 15245 Shady Grove Road, Suite 455 Rockville, MD 20850
Re: Rexahn Pharmaceuticals, Inc. Form 10 -K Filed March 14, 2016 File No. 001 -34079
Dear Mr. Jeong :
We have completed our review of your filing . We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff .
Sincerely,
/s/ Erin K. Jaskot, for
Show Raw Text
Mail Stop 4 546 November 15, 2016 Via E -mail Tae Heum Jeong Chief Financial Officer Rexahn Pharmaceuticals, Inc. 15245 Shady Grove Road, Suite 455 Rockville, MD 20850 Re: Rexahn Pharmaceuticals, Inc. Form 10 -K Filed March 14, 2016 File No. 001 -34079 Dear Mr. Jeong : We have completed our review of your filing . We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff . Sincerely, /s/ Erin K. Jaskot, for Suzanne Hayes Assistant Director Office of Healthcare and Insurance